Urologix Company Insiders
| ULGX Stock | USD 0.0001 0.00 0.00% |
Break down of Urologix's management performance can provide insight into the company performance.
| Bryon Merade Insider Chairman CEO |
Urologix |
Urologix Management Team Effectiveness
The company has return on total asset (ROA) of (0.0762) % which means that it has lost $0.0762 on every $100 spent on assets. This is way below average. Urologix's management efficiency ratios could be used to measure how well Urologix manages its routine affairs as well as how well it operates its assets and liabilities.Some institutional investors establish a significant position in pink sheets such as Urologix in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Urologix, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Urologix Workforce Comparison
Urologix is rated first in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 164. Urologix totals roughly 61.0 in number of employees claiming about 37% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.39) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.07) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.07. Urologix Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Urologix Price Series Summation is a cross summation of Urologix price series and its benchmark/peer.
Urologix Stakeholder
| Bryon Merade | Chairman CEO | Profile |
About Urologix Management Performance
The success or failure of an entity such as Urologix often depends on how effective the management is. Urologix management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Urologix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Urologix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia in the United States. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota. UROLOGIX operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 61 people.
Please note, the imprecision that can be found in Urologix's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Urologix. Check Urologix's Beneish M Score to see the likelihood of Urologix's management manipulating its earnings.
Urologix Workforce Analysis
Traditionally, organizations such as Urologix use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Urologix within its industry.Urologix Manpower Efficiency
Return on Urologix Manpower
| Revenue Per Employee | 229.7K | |
| Net Loss Per Employee | 124.7K |
Additional Tools for Urologix Pink Sheet Analysis
When running Urologix's price analysis, check to measure Urologix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Urologix is operating at the current time. Most of Urologix's value examination focuses on studying past and present price action to predict the probability of Urologix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Urologix's price. Additionally, you may evaluate how the addition of Urologix to your portfolios can decrease your overall portfolio volatility.